Elizabeth Gerstner

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Antiangiogenic therapy for glioblastoma
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Cancer J 18:45-50. 2012
  2. doi request reprint Diffusion and diffusion tensor imaging in brain cancer
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Semin Radiat Oncol 21:141-6. 2011
  3. doi request reprint Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
  4. doi request reprint Imaging and response criteria in gliomas
    Elizabeth R Gerstner
    Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Curr Opin Oncol 22:598-603. 2010
  5. ncbi request reprint Primary CNS lymphoma
    Elizabeth Gerstner
    Massachusetts General Hospital and Harvard Medical School, Department of Neurology, Boston, MA 02114, USA
    Expert Rev Anticancer Ther 7:689-700. 2007
  6. pmc Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    Elizabeth R Gerstner
    Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Neuro Oncol 12:466-72. 2010
  7. doi request reprint Primary central nervous system lymphoma
    Elizabeth R Gerstner
    Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Arch Neurol 67:291-7. 2010
  8. ncbi request reprint Anti-vascular endothelial growth factor therapy for malignant glioma
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
    Curr Neurol Neurosci Rep 9:254-62. 2009
  9. doi request reprint Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
    Elizabeth R Gerstner
    Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, 02114 MA, USA
    J Neurooncol 94:97-101. 2009
  10. pmc CNS Hodgkin lymphoma
    Elizabeth R Gerstner
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Blood 112:1658-61. 2008

Detail Information

Publications12

  1. pmc Antiangiogenic therapy for glioblastoma
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Cancer J 18:45-50. 2012
    ..Unfortunately, the response to anti-VEGF therapy is transient, and the majority of patients eventually relapsed, so more work is needed to understand the mechanisms of tumor escape...
  2. doi request reprint Diffusion and diffusion tensor imaging in brain cancer
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Semin Radiat Oncol 21:141-6. 2011
    ..DWI is increasingly being incorporated into clinical practice and clinical trials, but more work needs to be done to standardize acquisition techniques and analysis methods of DWI...
  3. doi request reprint Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
    ..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies...
  4. doi request reprint Imaging and response criteria in gliomas
    Elizabeth R Gerstner
    Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Curr Opin Oncol 22:598-603. 2010
    ..These new techniques are increasingly being incorporated into clinical trials and even into clinical practice. Therefore, it is important to be familiar with the available imaging techniques and their potential uses versus limitations...
  5. ncbi request reprint Primary CNS lymphoma
    Elizabeth Gerstner
    Massachusetts General Hospital and Harvard Medical School, Department of Neurology, Boston, MA 02114, USA
    Expert Rev Anticancer Ther 7:689-700. 2007
    ..Patients with HIV-associated primary CNS lymphoma have a worse prognosis but may respond to highly active antiretroviral therapy, whole-brain radiation therapy or therapies directed against the Epstein-Barr virus...
  6. pmc Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    Elizabeth R Gerstner
    Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Neuro Oncol 12:466-72. 2010
    ..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies...
  7. doi request reprint Primary central nervous system lymphoma
    Elizabeth R Gerstner
    Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Arch Neurol 67:291-7. 2010
    ..Unfortunately, although durable remissions may be achieved for some patients with PCNSL, the tumor relapses in most cases. In this review, we will focus on PCNSL in the immunocompetent host...
  8. ncbi request reprint Anti-vascular endothelial growth factor therapy for malignant glioma
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
    Curr Neurol Neurosci Rep 9:254-62. 2009
    ..However, because most patients eventually relapse, more work is needed to understand mechanisms of disease escape, including vascular co-option of native brain blood vessels...
  9. doi request reprint Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
    Elizabeth R Gerstner
    Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, 02114 MA, USA
    J Neurooncol 94:97-101. 2009
    ..Presence of psPD, independent of treatment, was associated with prolonged progression-free survival (P = 0.05) but not OS. psPD may be more common in combination therapy but most likely by a small margin...
  10. pmc CNS Hodgkin lymphoma
    Elizabeth R Gerstner
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Blood 112:1658-61. 2008
    ....
  11. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  12. pmc Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy
    Ovidiu C Andronesi
    Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Sci Transl Med 4:116ra4. 2012
    ..2HG detection by in vivo or ex vivo MRS enabled detailed molecular characterization of a clinically important subset of human gliomas. This has implications for diagnosis as well as monitoring of treatments targeting mutated IDH1...